Drug Profile
Research programme: anti-interleukin-6 antibody - EUSA/Vaccinex
Latest Information Update: 07 Jun 2021
Price :
$50
*
At a glance
- Originator Vaccinex
- Developer EUSA Pharma; Vaccinex
- Class Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in United Kingdom (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in United Kingdom (Parenteral)